231 related articles for article (PubMed ID: 32132142)
41. [Enzyme replacement therapy in Fabry's disease].
Alvarez L; del Pozo C; Trigueros M; Sánchez L; Albero MD; López-Menchero R; Ortega E
Nefrologia; 2005; 25(3):322-7. PubMed ID: 16053014
[TBL] [Abstract][Full Text] [Related]
42. Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy.
Morrissey RP; Philip KJ; Schwarz ER
Cardiovasc J Afr; 2011; 22(1):38-44. PubMed ID: 21298206
[TBL] [Abstract][Full Text] [Related]
43. [Fabry disease in light of recent review].
Uyama E
Brain Nerve; 2008 Nov; 60(11):1235-44. PubMed ID: 19069157
[TBL] [Abstract][Full Text] [Related]
44. [Results of enzyme replacement therapy in Fabry disease nephropathy].
Dussol B
Presse Med; 2007 Mar; 36 Spec No 1():1S43-7. PubMed ID: 17546767
[TBL] [Abstract][Full Text] [Related]
45. The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.
Morel CF; Clarke JT
Expert Opin Biol Ther; 2009 May; 9(5):631-9. PubMed ID: 19368525
[TBL] [Abstract][Full Text] [Related]
46. Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.
Lenders M; Brand E
J Am Soc Nephrol; 2018 Sep; 29(9):2265-2278. PubMed ID: 30093456
[No Abstract] [Full Text] [Related]
47. [Fabry disease].
Subran B; Montagner C; London J; Lidove O; Mauhin W
Rev Prat; 2020 May; 70(5):537-540. PubMed ID: 33058644
[TBL] [Abstract][Full Text] [Related]
48. Progressive renal failure despite long-term biweekly enzyme replacement therapy in a patient with Fabry disease secondary to a new α-galactosidase mutation of Leu311Arg (L311R).
Suzuki K; Miura N; Kitagawa W; Suzuki S; Komatsuda A; Nishikawa K; Watanabe D; Imai H
Clin Exp Nephrol; 2011 Dec; 15(6):916-20. PubMed ID: 21755431
[TBL] [Abstract][Full Text] [Related]
49. [Consensus for the study and treatment of Fabry disease. GETER Foundation].
García de Lorenzo A;
Med Clin (Barc); 2011 Jul; 137(4):178-83. PubMed ID: 21529855
[No Abstract] [Full Text] [Related]
50. [Fabry disease in cardiology: Diagnosis and therapeutic approaches].
Çavuşoğlu Y; Özpelit E; Arslan N; Demir M; Kahveci G; Onay H; Ökçün EÖB; Tufekcioglu O; Tülüce SY; Yıldırım GK
Turk Kardiyol Dern Ars; 2020 Dec; 48(Suppl 2):1-42. PubMed ID: 33476309
[TBL] [Abstract][Full Text] [Related]
51. [Fabry's disease (alpha-galactosidase-A deficiency): physiopathology, clinical signs, and genetic aspects].
Germain DP
J Soc Biol; 2002; 196(2):161-73. PubMed ID: 12360745
[TBL] [Abstract][Full Text] [Related]
52. Kidney transplantation and enzyme replacement therapy in patients with Fabry disease.
Cybulla M; Kurschat C; West M; Nicholls K; Torras J; Sunder-Plassmann G; Feriozzi S
J Nephrol; 2013; 26(4):645-51. PubMed ID: 23023720
[TBL] [Abstract][Full Text] [Related]
53. [Fabry disease: proposed guidelines from a French expert group for its diagnosis, treatment and follow-up].
Lidove O; Bekri S; Goizet C; Khau Van Kien A; Aractingi S; Knebelmann B; Choukroun G; Tsimaratos M; Redonnet-Vernhet I; Lacombe D; Jaussaud R
Presse Med; 2007; 36(7-8):1084-97. PubMed ID: 17276649
[TBL] [Abstract][Full Text] [Related]
54. [Efficacy of replacement enzyme therapy on central nervous system manifestations in Fabry's disease].
Besson G; Vadot W; Guellerin J
Rev Med Interne; 2010 Dec; 31 Suppl 2():S257-9. PubMed ID: 21211675
[TBL] [Abstract][Full Text] [Related]
55. Fabry disease and enzyme replacement therapy in classic patients with same mutation: different formulations--different outcome?
Politei J; Schenone AB; Cabrera G; Heguilen R; Szlago M
Clin Genet; 2016 Jan; 89(1):88-92. PubMed ID: 25817890
[TBL] [Abstract][Full Text] [Related]
56. A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1.
Connock M; Juarez-Garcia A; Frew E; Mans A; Dretzke J; Fry-Smith A; Moore D
Health Technol Assess; 2006 Jun; 10(20):iii-iv, ix-113. PubMed ID: 16729919
[TBL] [Abstract][Full Text] [Related]
57. The kidney in Fabry's disease.
Pisani A; Visciano B; Imbriaco M; Di Nuzzi A; Mancini A; Marchetiello C; Riccio E
Clin Genet; 2014 Oct; 86(4):301-9. PubMed ID: 24645664
[TBL] [Abstract][Full Text] [Related]
58. [The Fabry nephropathy: new insight in diagnosis, monitoring and treatment].
Mignani R
G Ital Nefrol; 2019 Jul; 36(4):. PubMed ID: 31373466
[TBL] [Abstract][Full Text] [Related]
59. Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy.
Nakano S; Tsukimura T; Togawa T; Ohashi T; Kobayashi M; Takayama K; Kobayashi Y; Abiko H; Satou M; Nakahata T; Warnock DG; Sakuraba H; Shibasaki F
PLoS One; 2015; 10(6):e0128351. PubMed ID: 26083343
[TBL] [Abstract][Full Text] [Related]
60. Angiokeratoma regression in a Fabry disease after treatment with agalsidase-beta: clinical effectiveness marker?
Fauchais AL; Prey S; Ouatara B; Vidal E; Sparsa A
J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):737-8. PubMed ID: 19925601
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
